Healio
Healio
CTS banner

Clinical Trials at the Summit meeting
ByArshad Khanani, MD, MA, FASRS
ByAnthony DeFino
ByDavid W. Mullin
Fact checked byChristine Klimanskis, ELS

Read more

July 03, 2024
3 min watch
Save

VIDEO: AVD-104 for geographic atrophy well tolerated at 3 months

ByArshad Khanani, MD, MA, FASRS
ByAnthony DeFino
ByDavid W. Mullin
Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, of Sierra Eye Associates in Nevada, presents 3-month data on AVD-104 for geographic atrophy.

The phase 2a SIGLEC trial investigated two low doses and two high doses of AVD-104 (Aviceda Therapeutics), which has a dual mechanism of action. According to Khanani, AVD-104 was well tolerated, with no drug-related serious adverse events reported. In addition, it demonstrated “multiple efficacy parameters,” including a significant reduction in GA growth over time and visual acuity improvements at the high dose.

The data “give us confidence to move forward” with a phase 2b study, Khanani said.

Sources/Disclosures

Collapse
Source:

Khanani A. Effect of AVD-104 on visual acuity and GA lesions in the SIGLEC trial. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Khanani reports consulting for and receiving research funding from Aviceda Therapeutics.

Read more about

geographic atrophy
retina
visual acuity
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content